Enable Accessibility Enable Accessibility

The research publication of the in vivo genome editing project for congenital muscular dystrophy in T-CiRA Joint Program were published online in Nature Communications on December 8th 2021.

December 16, 2021

The research publication of the in vivo genome editing project for congenital muscular dystrophy in T-CiRA Joint Program (Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice)
were published online in Nature Communications on December 8th 2021.
doi: 10.1038/s41467-021-26714-w

 

Paper Details

  • Journal: Nature Communications
  • Title: Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice doi: 10.1038/s41467-021-26714-w
  • Authors: Eriya Kenjo1,2, Hiroyuki Hozumi1,2, Yukimasa Makita1,2, Kumiko A. Iwabuchi2,3, Naoko Fujimoto2,3, Satoru Matsumoto1,2, Maya Kimura1, Yuichiro Amano1, Masataka Ifuku2,3, Youichi Naoe2,3, Naoto Inukai1,2, and Akitsu Hotta2,3
  • Author Affiliations:

1 T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
2 Takeda-CiRA Joint Program (T-CiRA), Kanagawa, Japan
3 Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan